Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention
Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar appeared on CW39's H-Town Live to discuss the company's innovative approach to breast cancer prevention. The segment highlighted Anixa's collaboration with the Cleveland Clinic in developing a novel vaccine targeting triple-negative breast cancer (TNBC), the most aggressive form of the disease.
The vaccine, currently in clinical trials, is designed to target a specific protein present in TNBC cells but absent in normal breast tissue. The goal is to stimulate the immune system to eliminate cancer cells before they develop into tumors, potentially eliminating the need for traditional treatments like chemotherapy and surgery.
Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar è apparso su H-Town Live di CW39 per discutere l'approccio innovativo della società alla prevenzione del cancro al seno. Il segmento ha evidenziato la collaborazione di Anixa con la Cleveland Clinic nello sviluppo di un nuovo vaccino mirato al cancro al seno triplo negativo (TNBC), la forma più aggressiva della malattia.
Il vaccino, attualmente in fase di sperimentazione clinica, è progettato per colpire una specifica proteina presente nelle cellule TNBC ma assente nel tessuto mammario normale. L'obiettivo è stimolare il sistema immunitario a eliminare le cellule tumorali prima che si sviluppino in tumori, riducendo potenzialmente la necessità di trattamenti tradizionali come la chemioterapia e la chirurgia.
El CEO de Anixa Biosciences (NASDAQ: ANIX), Dr. Amit Kumar, apareció en H-Town Live de CW39 para hablar sobre el enfoque innovador de la compañía en la prevención del cáncer de mama. El segmento destacó la colaboración de Anixa con la Cleveland Clinic en el desarrollo de una nueva vacuna dirigida al cáncer de mama triple negativo (TNBC), la forma más agresiva de la enfermedad.
La vacuna, actualmente en ensayos clínicos, está diseñada para dirigirse a una proteína específica presente en las células TNBC pero ausente en el tejido mamario normal. El objetivo es estimular el sistema inmunológico para eliminar las células cancerosas antes de que se conviertan en tumores, lo que potencialmente eliminaría la necesidad de tratamientos tradicionales como la quimioterapia y la cirugía.
Anixa Biosciences (NASDAQ: ANIX)의 CEO인 Amit Kumar 박사는 CW39의 H-Town Live에 출연하여 회사의 혁신적인 유방암 예방 접근 방식에 대해 논의했습니다. 이 세그먼트는 Anixa가 삼중 음성 유방암 (TNBC) 즉, 가장 공격적인 형태의 질병에 대한 새로운 백신을 개발하기 위해 Cleveland Clinic과 협력하고 있음을 강조했습니다.
현재 임상 시험 중인 이 백신은 TNBC 세포에 존재하지만 정상 유방 조직에는 없는 특정 단백질을 목표로 하도록 설계되었습니다. 목표는 암세포가 종양으로 발전하기 전에 면역 체계를 자극하여 제거하는 것으로, 전통적인 치료법인 화학요법과 수술의 필요성을 잠재적으로 없앨 수 있습니다.
Le PDG de Anixa Biosciences (NASDAQ: ANIX), Dr. Amit Kumar, est apparu dans l'émission H-Town Live de CW39 pour discuter de l'approche innovante de l'entreprise en matière de prévention du cancer du sein. Le segment a souligné la collaboration d'Anixa avec la Cleveland Clinic dans le développement d'un nouveau vaccin ciblant le cancer du sein triple négatif (TNBC), la forme la plus agressive de la maladie.
Le vaccin, qui est actuellement en essai clinique, est conçu pour cibler une protéine spécifique présente dans les cellules TNBC mais absente dans le tissu mammaire normal. L'objectif est de stimuler le système immunitaire pour éliminer les cellules cancéreuses avant qu'elles ne se développent en tumeurs, ce qui pourrait potentiellement éliminer le besoin de traitements traditionnels tels que la chimiothérapie et la chirurgie.
Der CEO von Anixa Biosciences (NASDAQ: ANIX), Dr. Amit Kumar, trat in der CW39-Sendung H-Town Live auf, um über den innovativen Ansatz des Unternehmens zur Prävention von Brustkrebs zu sprechen. Das Segment hob die Zusammenarbeit von Anixa mit der Cleveland Clinic zur Entwicklung eines neuartigen Impfstoffs ab, der auf dreifach negativem Brustkrebs (TNBC) abzielt, der aggressivsten Form der Krankheit.
Der Impfstoff, der sich derzeit in klinischen Prüfungen befindet, ist darauf ausgelegt, ein spezifisches Protein anzusprechen, das in TNBC-Zellen vorhanden, aber im normalen Brustgewebe nicht vorhanden ist. Das Ziel ist es, das Immunsystem zu stimulieren, um Krebszellen zu beseitigen, bevor sie sich zu Tumoren entwickeln, was potenziell die Notwendigkeit für traditionelle Behandlungen wie Chemotherapie und Chirurgie beseitigen könnte.
- Innovative vaccine development targeting triple-negative breast cancer (TNBC)
- Strategic collaboration with Cleveland Clinic
- Potential to prevent aggressive breast cancer before development
- None.
During the segment, Dr. Kumar highlighted Anixa's groundbreaking research in developing a novel breast cancer vaccine in collaboration with the Cleveland Clinic. The vaccine, currently in clinical trials, aims to prevent triple-negative breast cancer (TNBC), the most aggressive and difficult-to-treat form of the disease. By targeting a specific protein found in TNBC cells but absent in normal breast tissue, the vaccine seeks to stimulate the immune system to recognize and eliminate cancer cells before they can develop into full-blown tumor mass.
"We are dedicated to advancing science that can fundamentally change the way we approach breast cancer," said Dr. Kumar during the interview. "Our vaccine is designed to prevent the disease before it starts, potentially eliminating the need for invasive treatments such as chemotherapy and surgery in the future."
The discussion also addressed the broader impact of Anixa's research on the field of oncology, as well as the importance of continued innovation in cancer prevention.
To watch Dr. Amit Kumar's full interview on H-Town Live, please visit: https://www.youtube.com/watch?v=b8r5mJsJn74.
For more information about Anixa Biosciences and its ongoing clinical trials, please visit www.anixa.com.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-chairman--ceo-dr-amit-kumar-featured-on-cw39s-h-town-live-to-discuss-the-future-of-breast-cancer-prevention-302367010.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the current development stage of Anixa's (ANIX) breast cancer vaccine?
How does Anixa's (ANIX) breast cancer vaccine work?
What type of breast cancer does Anixa's (ANIX) vaccine target?
What are the potential benefits of Anixa's (ANIX) breast cancer vaccine?
